Greetings from the CEO

Our goal at GHPharm is to make

your future healthier and bring

happiness to your life today

We hope that all our customers are able to enjoy a happy and healthy life at a time when the average lifespan is reaching 100 years. We want you to live your life to the fullest rather than spend it fighting disease—all while staying happy and healthy until the age of 100 or even 150.
This is why GHPharm is always taking on new challenges.
The effects of the foods we have developed through our research can liberate our customers from refractory/intractable diseases and help them maintain healthy lives.
GHPharm is focusing all of its capabilities and technologies on the task of strengthening Korea’s foundational technologies to enable the development of new, original medicines.
We hope that you share our passion for our dreams and endeavors.
What we want most of all, however, is for you to lead a healthy life.
GHPharm aims to be a faithful companion in your efforts to maintain your current happiness and have a healthy future.

Gil Hong Park
CEO of GHPharm

Core capabilities

GHPharm’s core capabilities

illuminate our future

GHPharm develops new and original medicines and functional foods and cosmetics using naturally occurring substances (bracken (Pteridium aquilinum), royal Asian fern (Osmunda japonica), ginger (Zingiber officinale), etc.) and synthetic chemicals for the treatment of intractable chronic diseases, such as dementia, hair loss, arthralgia, rheumatoid arthritis, atopic dermatitis, and skin dryness.

GHPharm’s foundational technologies

focus on discovering new treatments

through constant

research and development

Bracken (called gosari in Korean) was traditionally a popular wild herb and known as “mountain-grown beef” for its wealth of nutrients and health benefits.
The pterosin found in bracken has been proven, through pre-clinical studies, to be effective in preventing and treating Alzheimer’s disease, degenerative arthritis, and the subsequently occurring arthralgia; improving the symptoms of diabetes and obesity; and alleviating hair loss. GHPharm has promoted the beneficial effects of bracken’s pterosin through articles published in esteemed medical journals both in Korea and overseas.
Because the process of removing the toxic substances that bracken contains also destroys pterosin, we had, until now, been unable to fully utilize bracken’s medicinal value. However, GHPharm has developed a foundational technology for safely extracting pterosin from bracken that is patent-registered in Korea (with patent applications submitted in the US, China, and EU).
Ginger has been used for thousands of years (recommended by the Ayurveda, a system of natural medicine developed in India, as an efficient remedy for osteoporosis) and continues to be used today. GHPharm discovered a substance in ginger, dehydrozingerone, that is an active ingredient in modern prevention/treatment methods for osteoporosis. Its effectiveness was proven through a pre-clinical study, the results of which were published in a major international journal. GHPharm has a registered patent for dehydrozingerone in Korea and has submitted patent applications for it in the US, China, and EU.
Osmunda japonica (known as Asian royal fern or gobi in Korean) was widely prescribed in Europe (especially northern Spain) as a remedy for rheumatoid arthritis, arthralgia, and bone fractures. Today, it is protected by law as an endangered species. In this plant, GHPharm discovered osmundacetone, an active ingredient for the treatment of bone diseases (e.g. rheumatoid arthritis), and published the results of its findings in a leading international journal. GHPharm has a registered patent for osmundacetone in Korea and has submitted patent applications for it in the US and China.

Timeline

2020

05: Gil Hong Park named as CEO
05: Company name changed to “GHPharm Co., Ltd.”
03: Signed joint development contract with Jirisan Dream for the development of a dementia-alleviating food (“Smart Jirisan bracken tea”)
01: Signed MOU with Gyeonggi-do Office and the Gyeonggido Business & Science Accelerator as a partner organization in research and biotechnology transfer for the expansion of biotechnologies and discovery of future growth engines
01: Received letter of intent from Baiyunjingkang (total: 7,000 beds) for clinical testing and joint commercialization activities

2019

10: Gained venture firm certification (from Korea Technology Finance Corporation)
09: Jae Sik Jeon named as CEO
06: Gil Hong Park named as CEO

2016

07: Signed research outsourcing contract with Korea University Medicine Industry-Academia Cooperative Group for the development of preventative/treatment medication for dementia and bone diseases
06: Jae Sik Jeon named as CEO
06: KOPHARM founded

Research on dementia

Patents

Patent registration number (Republic of Korea): 10-1934527·10-2085358
Patent application number (USA): 16/622,799
Patent application number (China): 201880038464.8
Patent application number (EU): 17913480.4-1109

A novel compound

for the prevention or treatment

of neurodegenerative diseases

that is comprised of new chemicals

and/or includes such new chemicals

as the active ingredient

Republic of Korea Patent Registration

Number: 10-1934527

Date registered: December 26, 2018
Patentees: GHPharm Co., Ltd., Korea University Research and Business Foundation, Gyeonggido Business & Science Accelerator
Main inventor: Gil Hong Park

A novel compound for the prevention

or treatment of neurodegenerative

diseases that is comprised of

pterosin compounds

and/or their derivatives

Republic of Korea Patent Registration

Number: 10-2085358

Date registered: February 3, 2020
Patentees: GHPharm Co., Ltd., Korea University Research and Business Foundation, Gyeonggido Business & Science Accelerator
Main inventor: Gil Hong Park

Research on hair loss prevention and hair growth promotion

Patents

Patent application number (Republic of Korea): 10-2020-0050364

A novel compound for the prevention

of hair loss and/or promotion

of hair growth that is comprised

of pterosin compounds

and/or their derivatives

Republic of Korea Patent Application

Number: 10-2020-0050364

Date registered: April 24, 2020
Assignees: GHPharm Co., Ltd., Korea University Research and Business Foundation
Main inventor: Gil Hong Park

Research on rheumatoid
arthritis, arthralgia, bone fracture

Patents

Patent registration number (Republic of Korea):10-1848489
Patent application number (USA) 16/338,354
Patent application number (China): 2019082600580310

A compound for the prevention

or treatment of bone diseases

that includes osmundacetone or a salt

that is able to pharmaceutically

tolerate osmundacetone

Republic of Korea Patent Registration

Number: 10-1848489

Date registered: April 6, 2018
Patentees: GHPharm Co., Ltd., Korea University Research and Business Foundation, Korea Institute of Radiological & Medical Sciences
Main inventor: Gil Hong Park

Research on osteoporosis

Patents

Patent registration number
(Republic of Korea):10-2114197
Patent application number (USA) 16/620,847
Patent application number (China): 2019122100014010
Patent application number (EU): 18837846.7

New dibenzylideneacetone derivative

and its use

Republic of Korea Patent Application

Number: 10-2114197

Date registered: May 18, 2020
Patentees: GHPharm Co., Ltd., Korea University Research and Business Foundation, Gyeonggido Business & Science Accelerator
Main inventor: Gil Hong Park

Research on atopic
dermatitis, xeroderma

Patents

Patent application number (Republic of Korea): 10-2018-0098863

A pharmaceutical compound for

the prevention or treatment of atopic

dermatitis or xeroderma (dry skin)

that includes dihydroxybenzoic acid

derivatives

Republic of Korea Patent Application

Number: 10-2018-0098863

Date registered: August 23, 2018
Assignees: GHPharm Co., Ltd., Korea University Research and Business Foundation, BIOGENOKOREA Co., Ltd.
Main inventor: Gil Hong Park

Research on COVID-19

Patents

Patent application number(Republic of Korea): 10-2020-0099490

Composition for preventing or

treating RNA virus infectious disease

comprising Pteridium aquilinum

extract or fraction thereof

Bracken water extract has been proven to have activated antiviral capabilities, as can be seen in its patented use by a research center (Registered patent (Korea): 10-2124592) in an independently-developed hand sanitizer.
The patents that are currently registered in China (CN102166276B, CN105125864A) confirm the existence of an antiviral substance in the organic extract (which includes bracken).

Contact Us!